EILEEN CAREY: Open Payments
NPI 1639614605 · TAUNTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 21 payments from 8 companies in 2025. Trend: 2023 $809 · 2024 $1,169 · 2025 $972
Food & beverage: $972
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $191 |
| ABBVIE INC. | 3 | $160 |
| Janssen Pharmaceuticals, Inc | 2 | $157 |
| E.R. Squibb & Sons, L.L.C. | 5 | $157 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
Products named: REXULTI, CAPLYTA, VRAYLAR, INVEGA SUSTENNA, COBENFY, AUSTEDO XR.
Industry payments across MA — which companies pay providers there.
